Urine collection and processing for protein biomarker discovery and quantification

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 4, 2010, Pages 953-959

  Eric Thomas, C ^a   Sexton, Wade ^a   Benson, Kaaron ^a   Sutphen, Rebecca ^b   Koomen, John ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA 1B GLYCOPROTEIN; BIOLOGICAL MARKER; BLADDER TUMOR ASSOCIATED ANTIGEN; CALRETICULIN; CATHEPSIN D; CLUSTERIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYSTATIN; CYSTATIN B; EOSINOPHIL PROTEIN X; GELATINASE B; GLYCOPROTEIN; INTERLEUKIN 6; NUCLEAR MATRIX PROTEIN 22; OSTEOPONTIN; PROGRANULIN; PROTEIN BNIP3; PROTEIN PCA3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; HUMAN; IMMUNOASSAY; KIDNEY CANCER; MULTIPLE MYELOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; SHORT SURVEY; STORAGE; URINALYSIS;

BIOLOGICAL MARKERS; HUMANS; PROTEINS; PROTEOMICS; SPECIMEN HANDLING;

EID: 77950818385     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0069     Document Type: Short Survey

References (67)

1. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007; 177: 361-368 (Pubitemid 47339533)
2. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006; 7: R80. (Pubitemid 44614864)
3. Coon JJ, Zürbig P, Dakna M, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics-Clinical Applications 2008; 2: 964-973
4. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL, The Multi Center Study Group. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology 1997; 50: 882-887
5. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293: 810-816 (Pubitemid 40250364)
6. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295: 299-305. (Pubitemid 43112958)
7. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002; 89: 369-373 (Pubitemid 34304360)
8. Vasudev NS, Sim S, Cairns DA, et al. Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer 2009; 101: 1175-1182
9. Anderson NS, Bermudez Y, Badgwell D, et al. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 2009; 112: 60-67
10. Corso A, Zappasodi P, Pascutto C, et al. Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications. Ann Hematol 2003; 82: 487-491 (Pubitemid 37069195)
11. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009; 15: 1024-1031
12. Goranova V, Spassov E. Prognostic significance of the immunological variant in patients with multiple myeloma. Folia Med (Plovdiv) 1999; 41: 164-167
13. Hazzaa SM, Elashry OM, Afifi IK. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res 2009. Online Publication Only. PMID: 19757199. SpringerLink ISSN 1219-4956 (Print) 1532-2807 (Online) doi 10.1007/s12253-009-9196-3.
14. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009; 6: 255-261
15. Kageyama S, Isono T, Iwaki H, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem 2004; 50: 857-866
16. Kaya K, Ayan S, Gokce G, Kilicarslan H, Yildiz E, Gultekin EY. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol 2005; 39: 25-29 (Pubitemid 40380439)
17. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007; 6: 2631-2639 (Pubitemid 47122358)
18. Lovat F, Bitto A, Xu SQ, et al. Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 2009; 30: 861-868
19. Sfiridaki A, Miyakis S, Tsirakis G, et al. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med 2005; 43: 934-938 (Pubitemid 41461143)
20. Sirohi B, Powles R, Kulkarni S, et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 2001; 28: 29-37.
21. Theodorescu D, Schiffer E, Bauer HW, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics-Clinical Applications 2008; 2: 556-570
22. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 2009; 101: 98-105.
23. Yoneda K, Iida H, Endo H, et al. Identification of cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009; 35: 33-40.
24. Koomen JM, Haura EB, Bepler G, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008; 7: 1780-1794
25. Parekh RS, Kao WH, Meoni LA, et al. Reliability of urinary albumin, total protein, and creatinine assays after prolonged storage: the Family Investigation of Nephropathy and Diabetes. Clin J Am Soc Nephrol 2007; 2: 1156-1162
26. Crosley LK, Duthie SJ, Polley AC, et al. Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics. Genes Nutr 2009; 4: 95-102.
27. Goligorsky MS, Addabbo F, O'Riordan E. Diagnostic potential of urine proteome: a broken mirror of renal diseases. J Am Soc Nephrol 2007; 18: 2233-2239 (Pubitemid 47203837)
28. Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009; 8: 268-281
29. Lankisch P, Wessalowski R, Maisonneuve P, Haghgu M, Hermsen D, Kramm CM. Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr Blood Cancer 2006; 46: 767-772 (Pubitemid 43726425)
30. Conti M, Moutereau S, Esmilaire L, et al. Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C. Clin Chem Lab Med 2009; 47: 1553-1556
31. Conti M, Zater M, Lallali K, et al. Absence of circadian variations in urine cystatin C allows its use on urinary samples. Clin Chem 2005; 51: 272-273 (Pubitemid 40024060)
32. Roos JF, Doust J, Tett SE, Kirkpatrick CMJ. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-A meta-analysis. Clin Biochem 2007; 40: 383-391 (Pubitemid 46303950)
33. Lemm G, Kuppers J, Frey R, Wingender W, Kuhlmann J. Monitoring of proteinuria in phase I studies in healthy male subjects. Eur J Clin Pharmacol 1998; 54: 287-294 (Pubitemid 28328011)
34. Thongboonkerd V, Chutipongtanate S, Kanlaya R. Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J Proteome Res 2005; 5: 183-191 (Pubitemid 43100811)
35. Zhou H, Yuen PS, Pisitkun T, et al. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int 2006; 69: 1471-1476
36. Havanapan PO, Thongboonkerd V. Are protease inhibitors required for gel-based proteomics of kidney and urine? J Proteome Res 2009; 8: 3109-3117
37. Thongboonkerd V, Mungdee S, Chiangjong W. Should urine pH be adjusted prior to gel-based proteome analysis? J Proteome Res 2009; 8: 3206-3211
38. Thongboonkerd V. Practical points in urinary proteomics. J Proteome Res 2007; 6: 3881-3890
39. Castagna A, Cecconi D, Sennels L, et al. Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res 2005; 4: 1917-1930 (Pubitemid 41814257)
40. Nabi G, N'Dow J, Hasan TS, Booth IR, Cash P. Proteomic analysis of urine in patients with intestinal segments transposed into the urinary tract. Proteomics 2005; 5: 1729-1733 (Pubitemid 40593278)
41. Pieper R, Gatlin CL, McGrath AM, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004; 4: 1159-1174
42. Rehman I, Azzouzi AR, Catto JW, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64: 1238-1243 (Pubitemid 39647082)
43. Ru QC, Katenhusen RA, Zhu LA, et al. Proteomic profiling of human urine using multi-dimensional protein identification technology. J Chromatogr A 2006; 1111: 166-174
44. Sun W, Li F, Wu S, et al. Human urine proteome analysis by three separation approaches. Proteomics 2005; 5: 4994-5001. (Pubitemid 43016918)
45. Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen S-T. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics 2005; 5: 1140-1149 (Pubitemid 40469041)
46. Oh J, Pyo JH, Jo EH, et al. Establishment of a near-standard twodimensional human urine proteomic map. Proteomics 2004; 4: 3485-3497
47. Soldi M, Sarto C, Valsecchi C, et al. Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 2005; 5: 2641-2647 (Pubitemid 40966491)
48. Smith G, Barratt D, Rowlinson R, Nickson J, Tonge R. Development of a high-throughput method for preparing human urine for twodimensional electrophoresis. Proteomics 2005; 5: 2315-2318 (Pubitemid 40835399)
49. Lee RS, Monigatti F, Briscoe AC, Waldon Z, Freeman MR, Steen H. Optimizing sample handling for urinary proteomics. J Proteome Res 2008; 7: 4022-4030
50. HKUPP. Standard Protocol for Urine Collection and Storage. [cited; Available from: http://www.hkupp.org/Urine%20collectiion%20Documents.htm.
51. Stahl-Zeng J, Lange V, Ossola R, et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteomics 2007; 6: 1809-1817 (Pubitemid 350031682)
52. Kuzyk MA, Smith D, Yang J, et al. Multiple reaction monitoringbased, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009; 8: 1860-1877
53. Eijan AM, Sandes E, Puricelli L, Bal De Kier Joffe E, Casabe AR. Cathepsin B levels in urine from bladder cancer patients. Oncol Rep 2000; 7: 1395-1399
54. Szajda SD, Snarska J, Jankowska A, Roszkowska-Jakimiec W, Puchalski Z, Zwierz K. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients. Hepatogastroenterology 2008; 55: 388-393 (Pubitemid 351741467)
55. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58: 1395-1399
56. Pories SE, Zurakowski D, Roy R, et al. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008; 17: 1034-1042
57. Sherief MH, Low SH, Miura M, Kudo N, Novick AC, Weimbs T. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol 2003; 169: 1530-1534
58. Di Carlo A, Terracciano D, Mariano A, Macchia V. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep 2006; 15: 1321-1326
59. Muir C, Chung LW, Carson DD, Farach-Carson MC. Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clin Exp Metastasis 2006; 23: 75-86.
60. Lin J, Lai M, Huang Q, Ruan W, Ma Y, Cui J. Reactivation of IGFBP7 by DNA demethylation inhibits human colon cancer cell growth in vitro. Cancer Biol Ther 2008; 7: 1896-1900
61. Akaogi K, Okabe Y, Funahashi K, et al. Cell adhesion activity of a 30-kDa major secreted protein from human bladder carcinoma cells. Biochem Biophys Res Commun 1994; 198: 1046-1053
62. Ye B, Skates S, Mok SC, et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006; 12: 432-441
63. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006; 5: 573-588
64. Kushnir MM, Mrozinski P, Rockwood AL, Crockett DK. A depletion strategy for improved detection of human proteins from urine. J Biomol Tech 2009; 20: 101-108
65. Fortin T, Salvador A, Charrier JP, et al. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal Chem 2009; 81: 9343-9352
66. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of Thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008; 54: 1796-1804
67. Anderson NL, Anderson NG, Pearson TW, et al. A human proteome detection and quantitation project. Mol Cell Proteomics 2009; 8: 883-886